Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy

Osteoporosis is age-related deterioration in bone mass and micro-architecture. Denosumab is a novel human monoclonal antibody for osteoporosis. It is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, which binds to and inhibits osteoblast-produced RANKL, in turn reduces the binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ning, Zhang, Zong-Kang, Yu, Yuanyuan, Zhuo, Zhenjian, Zhang, Ge, Zhang, Bao-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240042/
https://www.ncbi.nlm.nih.gov/pubmed/32478071
http://dx.doi.org/10.3389/fcell.2020.00325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240042/
https://www.ncbi.nlm.nih.gov/pubmed/32478071
http://dx.doi.org/10.3389/fcell.2020.00325

Ejemplares similares